Ex-Sanofi Exec Stoeckli Primes Glenmark’s Cancer Therapy Ambitions

Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.

Dr Kurt Stoeckli, says that moving to Glenmark Pharmaceuticals Ltd. from Sanofi was all about a “perfect match.” While the former group vice president for the French multinational’s global biopharmaceuticals division may have been used to big pharma R&D budgets and scale, Stoeckli says that he was drawn to the Indian firm by its sheer potential – “people, project and science” - and what the company “could make” in the years to come.

“I just found that this is a perfect match, where I could bring complementarity and experience that I have gone...